[HTML] frontiersin.org

[HTML][HTML] Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets–beyond B lymphocytes

S Zhu, S Gokhale, J Jung, E Spirollari, J Tsai… - Frontiers in cell and …, 2021 - frontiersin.org
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
被引用次数：27 相关文章

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets–Beyond B Lymphocytes

S Zhu, S Gokhale, J Jung, E Spirollari, J Tsai, J Arceo… - 2021 - agris.fao.org
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets–Beyond B Lymphocytes

S Zhu, S Gokhale, J Jung, E Spirollari… - Frontiers in Cell …, 2021 - researchwithrutgers.com
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
[HTML] nih.gov

[HTML][HTML] Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets–Beyond B Lymphocytes

S Zhu, S Gokhale, J Jung, E Spirollari… - Frontiers in Cell and …, 2021 - ncbi.nlm.nih.gov
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets-Beyond B Lymphocytes.

S Zhu, S Gokhale, J Jung, E Spirollari… - Frontiers in Cell and …, 2021 - europepmc.org
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets-Beyond B Lymphocytes

S Zhu, S Gokhale, J Jung… - Frontiers in cell …, 2021 - pubmed.ncbi.nlm.nih.gov
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …